Company profile: Harpoon Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage immunotherapy developing novel T cell-engaging biologic therapies that harness the body’s immune system to direct patients’ T cells to kill target cells in cancer and other diseases, including the TriTAC Technology antibody-based drug discovery platform designed to enhance immune targeting and killing of cancer cells.
Products and services
- T Cell Engagers: Custom-engineered proteins that direct a patient’s T cells to kill target cells expressing specific proteins, harnessing the immune system to treat cancer and other diseases
- TriTAC Technology: Novel antibody-based drug discovery platform engineered to enhance the patient’s immune system’s ability to target and kill cancer cells
- T-Cell Recruiting Biologic Therapies: Clinical-stage biologic therapies that harness the immune system to treat patients suffering from cancer and other diseases by recruiting T cells to target cells
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Harpoon Therapeutics
Eureka Therapeutics
HQ: United States
Website
- Description: Provider of T-cell therapies via the ARTEMIS Cell Receptor Platform to engineer T cells to target and destroy cancer cells; the E-ALPHA Phage Display Platform to generate specific antibodies against cancer targets, including TCR-mimic antibodies for solid tumors; and an Expanded Access Policy offering investigational cell therapy under certain conditions to patients with serious or life-threatening diseases who have no other treatment options.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Eureka Therapeutics company profile →
Crescendo Biologics
HQ: United Kingdom
Website
- Description: Provider of Humabody VH-based antibody therapeutics and a discovery platform enabling rapid discovery of fully human VH domains for small, stable multi-specifics. Offerings include CB307 (PSMA x CD137 bispecific in trial for metastatic castration-resistant prostate cancer), CB213 (preclinical PD-1 x LAG-3), and ZL-1102 (topical IL-17A; licensed to Zai Lab). Also engages in partnered and licensed programs with BioNTech, Takeda.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Crescendo Biologics company profile →
Faron Pharmaceuticals
HQ: Finland
Website
- Description: Provider of clinical-stage biopharmaceutical therapies targeting acute organ trauma, vascular damage, and cancer immunotherapy, including bexmarilimab, a humanized monoclonal antibody against Clever-1 on macrophages to modify the tumor microenvironment and boost anti-tumor immune response, and Traumakine, an intravenous interferon beta-1a to prevent multiorgan dysfunction and mitigate CAR-T side effects (cytokine release syndrome, neurotoxicity).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Faron Pharmaceuticals company profile →
XNK Therapeutics
HQ: Sweden
Website
- Description: Provider of clinical-stage autologous NK cell–based immunotherapies for cancer, leveraging a proprietary platform for development and manufacture. Pipeline includes evencaleucel in Phase II for multiple myeloma with isatuximab, and preclinical candidates XNK02 (AML), XNK03 (urothelial cancer), and XNK04 (hepatocellular carcinoma). Holds a GMP manufacturing license.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full XNK Therapeutics company profile →
Elusys Therapeutics
HQ: United States
Website
- Description: Provider of antibody therapeutics for infectious disease, including ANTHIM (obiltoxaximab), a monoclonal anthrax antitoxin used to mitigate the effects of anthrax exposure, licensed in the United States and Canada, and NYXTHRACIS (obiltoxaximab), the same antitoxin licensed in Great Britain and the European Union.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Elusys Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Harpoon Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Harpoon Therapeutics
2.2 - Growth funds investing in similar companies to Harpoon Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Harpoon Therapeutics
4.2 - Public trading comparable groups for Harpoon Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →